• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Ubiquilin-3 (UBQLN3)

ACP10999

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP10999 Target NameUBQLN3
Target SynonymsTUP1; Ubiquilin 3; Ubiquilin-3; UBQL3_HUMAN; UBQLN3FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range1-655
Protein LengthFull length proteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ9H347
Background Information
  • Uniprot Id

    Q9H347

  • Target Species

    Human

  • Target Name

    UBQLN3

  • Target Full Name

    Ubiquilin-3

  • Target Synonyms

    TUP1; Ubiquilin 3; Ubiquilin-3; UBQL3_HUMAN; UBQLN3

  • Target Background

    This gene encodes a ubiquitin-like protein (ubiquilin) that shares a high degree of similarity with related products in yeast, rat and frog. Ubiquilins contain an N-terminal ubiquitin-like domain and a C-terminal ubiquitin-associated domain. They physically associate with both proteasomes and ubiquitin ligases, and are thus thought to functionally link the ubiquitination machinery to the proteasome to affect in vivo protein degradation. This gene is specifically expressed in the testis. It has been suggested that this gene may regulate cell-cycle progression during spermatogenesis, however, it has been shown that the ortholgous mouse gene is dispensable for embryonic development and spermatogenesis.

Inquire Recombinant Human Ubiquilin-3 (UBQLN3) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification